How Precision Medicine Will Transform the Pharmaceutical and Healthcare Industries

Strategy+Business

And although the pharmaceutical and healthcare industries know this is the way forward, they face some significant hurdles Precision medicine combines business opportunities with clinical health benefits.

Why the Pharmaceutical Industry is Booming in Japan - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN

Harvard Business

That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna v. Pfizer: What the Patent Infringement Suit Means for Biotech

Harvard Business Review

Business and society Covid Public-private partnerships Organizational culture Public relations Product development R&D Management Strategy Pharmaceutical industry Digital ArticleAfter an unusual period of cooperation, drug companies are suing each other again.

The Pharmaceutical Industry Needs a Customer-Centric Digital Transformation - SPONSOR CONTENT FROM INDEGENE

Harvard Business

Sponsor content from Indegene. Innovation Customer service Technology Sponsor Content

White Coats, Black Scientists

Harvard Business

Race Pharmaceuticals Digital ArticleHow scientific institutions can address systemic racism.

What It Takes to Lead a Disease Research Foundation

Harvard Business

Leadership & Managing people Pharmaceuticals Healthcare Digital ArticleThree strategies to stay laser focused on the path to a cure.

Addressing Demographic Disparities in Clinical Trials

Harvard Business

Research & development Diversity Demographics Healthcare Pharmaceuticals Digital ArticleWomen, people of color, and the elderly are often underrepresented in the data.

Data 36

Where Telemedicine Falls Short

Harvard Business

Technology Healthcare Pharmaceuticals Digital ArticleIt offers enormous benefits — but can’t replace in-person visits.

It’s Time for a New Kind of Electronic Health Record

Harvard Business

Technology Analytics Healthcare Technology Pharmaceuticals Government Digital ArticleWe need to shift from reactive to preventative care.

Drug Pricing in the United States

Tom Spencer

1 Pharmaceutical companies are unique in their capacity, due to little regulation and oversight, to raise prices. Because of the ability of health insurance companies and benefit executives at leading pharmaceutical companies to negotiate discounts and benefit packages, many in the industry argue that list prices on prescription drugs aren’t actually a reliable indicator of what Americans pay. In order to limit competition, pharmaceutical companies rely heavily on patent laws.

Adopting AI in Health Care Will Be Slow and Difficult

Harvard Business

Technology Analytics Regulation Healthcare Pharmaceuticals Technology Digital ArticleA few key obstacles and how to overcome them.

The Future of Drug Trials Is Better Data and Continuous Monitoring

Harvard Business

Research & development Technology Pharmaceuticals Healthcare Technology Digital ArticleIt will help patients and bring new treatments to market faster.

The U.S. Can Lower Drug Prices Without Sacrificing Innovation

Harvard Business

Large pharmaceutical companies are nowhere near as important to real drug innovation as they purport to be. Government policy and regulation Innovation Digital Article

How Japan Is Creating New Opportunities in the Field of Regenerative Medicine - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN

Harvard Business

Regeneratives are pharmaceutical cell therapy products that replace or restore cells and tissues lost to disease or aging. “To be able to do that, they need to entice companies to come to Japan, and they need to entice their own pharmaceutical companies to license in and obtain the best.” It includes a designation system that promotes R&D in Japan aimed at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines.

The Upside of Losing Innovative Employees to Competitors

Harvard Business

A study of pharmaceutical firms finds that it leads to valuable collaborations. Research & development Joint ventures Competition Digital Article

The Promise and Challenge of Big Data for Pharma

Harvard Business

The emergence of big data, as well as advancements in data science approaches and technology, is providing pharmaceutical companies with an opportunity to gain novel insights that can enhance and accelerate drug development. The pharmaceuticals industry has seen an explosion in the amount of available data beyond that collected from traditional, tightly controlled clinical trial environments. Analytics Data Research & development Healthcare Pharmaceuticals Digital Article

The One Meeting that Reliably Produces Huge Consulting Projects

David A Fields

There were about fifteen of us—three from my team and a dozen client personnel—in a conference room at the headquarters of one of the world’s largest pharmaceutical companies. The meeting was long. Lively, but grueling. It took an investment of time and even a bit of cash to pull together. (I I brought two, contract consultants in to prep and attend the meeting.)

Conflict-of-Interest Rules Are Holding Back Medical Breakthroughs

Harvard Business

In some states, accepting a cup of coffee from a pharmaceutical company must be reported, so “education” over lavish meals or in resort settings has largely receded. Guided by a refreshed ethical framework, pharmaceutical companies, in partnership with researchers and clinicians, can help accelerate the spread of knowledge of new clinical science, which now is notoriously slow. Ethics Research & development Government Healthcare Pharmaceuticals Digital Article

325: Maria Lizza Bowen—Do You Feel Stuck? Time To "See, Feel And Think In New Ways"

On the Brink Podcast

Today we have Maria Lizza Bowen, a scientist and Oncology Clinical Development Director with almost 30 years in the pharmaceutical industry. Hear how to understand yourself better and embrace the new.

Research: Innovation Suffers When Drug Companies Merge

Harvard Business

This is especially true in pharmaceutical markets where new and affordable drugs can improve and even save the lives of many people. What makes our study unique is that we compared firms’ innovation activities not only before and after acquisitions, but we also compared those merging companies to firms in similar pharmaceutical markets without merger activities. And so pharmaceutical firms appear to be benefitting from regulators’ incomplete decision process.

Fixing Pharma’s Incentives Problem in the Wake of the U.S. Opioid Crisis

Harvard Business

Since 1999, three years after OxyContin was unveiled by Purdue Pharmaceuticals, the rate of drug overdoses in the U.S. Meanwhile, the amount of prescription opioids sold by pharmaceutical companies has quadrupled, despite no proliferation in the amount of reported pain. One place to start might be a fresh look at the incentive compensation structure in the pharmaceutical industry. Sales Marketing Pharmaceuticals Digital Article

3 Business Models That Could Bring Million-Dollar Cures to Everyone

Harvard Business

Innovation Business models Entrepreneurship Healthcare Pharmaceuticals Technology Digital ArticleTEK IMAGE/SCIENCE PHOTO LIBRARY/Getty Images. When the FDA issued its first approval for a gene therapy for an inherited disease nearly a year ago—a cure for a type of blindness—it was heralded as breakthrough, a moment decades in the making.

What Cancer Researchers Can Learn from Direct-to-Consumer Companies

Harvard Business

Organizations collecting patient data — including academic medical centers, foundations that sponsor cancer research, and pharmaceutical companies — must first identify the needs, pains, hopes, expectations, and behaviors of each person living with cancer. Marketing Research & development Social platforms Non-profit Healthcare Pharmaceuticals Digital Article

Sexual Harassment Is Rampant in Health Care. Here’s How to Stop It.

Harvard Business

Organizational culture Gender Policy Corporate governance Healthcare Pharmaceuticals Digital ArticleCarmen Martínez Torrón/Getty Images. Many factors make an organization prone to sexual harassment: a hierarchical structure, a male-dominated environment, and a climate that tolerates transgressions — particularly when they are committed by those with power. Medicine has all three of these elements.

A New Approach to Safely Sharing Cancer Patients’ Data

Harvard Business

Shared value Research & development Collaboration Healthcare Pharmaceuticals Digital ArticleIt is well understood that achieving the full potential of precision medicine for all cancer patients depends on the sharing of patients’ genomic and molecular data and clinical information.

How to Lead from the Jumpseat & Help Your People Thrive w/Peter Docker Ep#130

Strategic Planning and Management Insights

Now he's a keynote speaker and consultant working with the most senior levels in oil & gas, construction, mining, pharmaceuticals, banking, television, film, media, manufacturing and services.

s+b Trend Watch: The Coming Digital Healthcare Landscape

Strategy+Business

Looking toward the future, pharmaceutical companies and other stakeholders will adopt existing technologies and develop new ones, creating a more connected digital healthcare ecosystem Doctors and patients are starting to use digital tools to manage healthcare more efficiently.

A Pharma Playbook for Success in Southeast Asia

BCG

To capture the immense opportunities in emerging markets, pharmaceutical companies require highly targeted strategies. By 2020, emerging markets will account for more than 30% of pharmaceutical sales growth worldwide. Southeast Asia alone is expected to generate $40 billion in pharmaceutical sales by 2020. Article Tuesday, August 23, 2016.

How Pharma Companies Can Keep Winning in China’s Changing Market

BCG

Focus Tuesday, November 22, 2016 Big shifts are underway in China’s pharmaceutical market. They will shape the marketplace for more than 90% of drug sales for the next decade for multi-national corporations and domestic players. While the long-term direction is becoming clear, the transition period over the next three to five years will be particularly challenging.

Don’t call me Big Nose

Consultants' Consultant

Felicity is an internal consultant for a pharmaceutical company. Consultants Consultant: “Don’t call my wife Big Nose!” Monty Python, Life of Brian How many times today have you had to say no? Or how many times SHOULD you have said no (but didn’t). At the beginning of every financial year, she is charged with making sure every […]. The post Don’t call me Big Nose appeared first on Consultants' Consultant. Consulting Well Training programs

Getting the Work Done with Project Management

Gina Abudi PM

For the last three years, one of Abudi Consulting Group’s clients, a global pharmaceutical organization, has been working with us to provide training for their employees at all levels in how to use project management best practices to accomplish work. A Client Story.

Is Pharma Ready for the Future?

Strategy+Business

The pharmaceuticals industry is facing a radical transformation in the way it manufactures medicine. Companies that want to succeed in the future need to move from the current pharma manufacturing paradigm to one that includes new technologies such as continuous manufacturing and 3D printing

Debating the Sackler Family Role in the Opioid Crisis, and Using AI Bots to Conduct Job Interviews

Harvard Business

Youngme, Felix, and Mihir discuss whether pharmaceutical players like the Sackler family members should be held accountable for the current opioid crisis. They then debate the growing reliance on artificial intelligence bots by human resource departments in the job screening process. Social responsibility Economics & Society Technology Audio

Another Round of Ransomware Cyberattacks Hits Major Companies Across the Globe: Assessing the Blame

MishTalk

Pharmaceutical company Merck, Danish shipper Maersk, advertising group WPP Group, Ukrainian banks, and Russian oil company Rosneft all report significant intrusions on their computer systems. Another version of the “WannaCry” ransomware virus has gone viral, this one dubbed “Petya” by some and “GoldenEye” by others. Alternatively, some security experts say it is an entirely new virus.

Success Story: A New Factory, a New Training Methodology, a New Beginning

Clarity Consultants

Our story begins in 2013, when a major global pharmaceutical firm launched a technology transfer project from one of its US factories to a new factory being constructed in Europe. For years the US factory had been the sole producer of the company’s successful drug to combat a persistent blood disease that, at best was a lifelong nuisance and, at worst was potentially fatal.

Price Gouging and the Dangerous New Breed of Pharma Companies

Harvard Business

For 78-year-old Tony, 3,4 DAP — which can be obtained at low cost from compounding pharmacies or for free through a compassionate-use program supported by a small privately held company, Jacobus Pharmaceuticals — is a lifesaver. Pharmaceutical companies traditionally invest heavily in research and development. Ionis Pharmaceutical has been especially successful in creating a pipeline of these drugs, such as Nusinersen, a promising therapy for spinal muscular atrophy.

Do You Know Who Has Influence on Your Projects?

Gina Abudi

One project manager, who works for a pharmaceutical company, is working on a major project that crosses a number of divisions within the organization. I have seen too many project managers who don’t understand their stakeholders – and, specifically, the influence stakeholders may have on the project. I have been working with him from the [.]. The post Do You Know Who Has Influence on Your Projects? appeared first on Gina Abudi.

Capturing the MRO Advantage in Manufacturing

BCG

A pharmaceutical manufacturer reduced the idle time associated with breakdowns through more aggressive spare-part inventory management. Focus Wednesday, November 23, 2016. To ensure their competitiveness in the rapidly changing global marketplace, manufacturers in all regions are seeking ways to radically reduce their costs. Maintenance, repair, and operations (MRO) is a critical area. MRO spending, which includes expenditures for services and spare parts, ranges from 0.5% to 4.5%

2 Leadership Tactics for Motivating Your Team

Organizational Talent Consulting

American Journal of Pharmaceutical Education, 81(3), 58. Building a highly-skilled self-directed team and paying them well doesn't guarantee success. Motivation helps to explain the differences between times when employees just show up versus getting things done.

How Pharma Companies Game the System to Keep Drugs Expensive

Harvard Business

The 1984 Drug Price Competition and Patent Term Restoration Act gave pharmaceutical companies exclusive protections for innovating a new drug. ” By selling a drug they’re already making under a different name, pharmaceutical firms are effectively extending their monopoly for another six months. Another way pharmaceutical firms are thwarting generics is by restricting access to samples for testing. Regulation Branding Manufacturing Pharmaceuticals Digital Article